Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838562 | 0.84 | HTR2A (0.53) | HTR2ASLC6A4KCNH2ALDH1A1HSP90AA1 | |
| SCHEMBL20535365 | 0.83 | TDP1 (0.57) | TDP1ALDH1A1HSP90AA1TP53ERN1 | |
| SCHEMBL5321373 | 0.82 | LMNA (0.61) | HTR2ASLC6A4KCNH2TDP1ALDH1A1 | |
| SCHEMBL23709944 | 0.82 | SLC6A4 (0.50) | HTR2ASLC6A4KCNH2TDP1ERN1 | |
| SCHEMBL5497557 | 0.82 | VCAM1 (0.49) | TDP1ALDH1A1 | |
| SCHEMBL5837353 | 0.81 | HTR2A (0.57) | HTR2ASLC6A4KCNH2ALDH1A1HSP90AA1 | |
| SCHEMBL5991889 | 0.81 | LMNA (0.46) | HTR2ASLC6A4KCNH2TDP1ALDH1A1 | |
| SCHEMBL5989078 | 0.81 | HTR2A (0.52) | HTR2ASLC6A4KCNH2TDP1ALDH1A1 | |
| SCHEMBL20536242 | 0.80 | LMNA (0.62) | TDP1ALDH1A1ERN1P2RY1 | |
| SCHEMBL19563670 | 0.79 | ALDH1A1 (0.55) | SLC6A4TDP1ALDH1A1ERN1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| WO-2018191146-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | HTR2A 4448/4885SLC6A4 4819/4885KCNH2 4734/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | HTR2A 4490/4885SLC6A4 4806/4885KCNH2 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.